Abstract 5295: Latent class longitudinal modeling of CTCs in ER+ metastatic breast cancer patients

Terry Hyslop(Thomas Jefferson University), Massimo Cristofanilli(Cornell University), James M. Reuben(The University of Texas MD Anderson Cancer Center), Xuechan Li(Duke University), Mario Giuliano(Regione Campania), Hallgeir Rui(Thomas Jefferson University), Rui Duan(Harvard University), Antonio Giordano(Harvard University), Marlana Orloff(Heidelberg University)
Cancer Research
August 1, 2015
10.1158/1538-7445.am2015-5295
Cited by 0

Related Papers

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
|New England Journal of Medicine|2021|869
Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell Lymphoma
|Journal of Clinical Oncology|2001|610